The short-acting insulin market is estimated to be valued at USD 9.5 Bn in 2024 and is expected to reach USD 13.2 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2031. The market is expected to grow steadily over the forecast period due to the increasing prevalence of diabetes globally and rise in healthcare expenditure.

The short-acting insulin market is expected to witness substantial growth over the coming years. Key growth factors for the market include the rising incidence of diabetes, growing geriatric population, and increasing healthcare spending.

Moreover, the development of cost-effective biosimilar insulin drugs and the introduction of innovative fast-acting insulin analogs are also contributing to market growth. However, strict regulations for the approval of insulin drugs and the availability of alternative treatment options for diabetes may hamper market growth during the forecast period. Overall, increasing diabetes prevalence and improved access to diagnosis and treatment define the future growth trajectory of the short-acting insulin market.

Market Driver - Increasing prevalence of diabetes globally

The prevalence of diabetes is growing at an alarming rate on a global scale. According to expert projections, by the year 2030 diabetes will affect around 552 million people worldwide, with developing nations shouldering much of this burden. As diabetes rates multiply across worldwide population, so does the demand for effective treatment and management regimens. Currently type 2 diabetes accounts for around 90% of all diabetes cases diagnosed globally. With largely sedentary modern lifestyles and worsening obesity epidemic trends, the number of type 2 diabetes patients has skyrocketed over the past few decades. As it is a chronic lifelong condition with no permanent cure available as yet, patients rely on long term medication to keep blood sugar levels in control.

Short acting insulin remains a cornerstone agent for managing postprandial blood sugar spikes seen after meal consumption, especially in type 1 diabetes patients who entirely lack natural insulin production. It works by closely mimicking the body's own rapid release of insulin post food intake. Its quicker onset of action and shorter duration of activity in the body makes it very effective for pre-meal administration and controlling post-meal hyperglycemia. With rising diabetes population worldwide, the pool of patients requiring intensive insulin regiment which includes short acting insulin, has swelled substantially. Countries with limited access to healthcare are witnessing dire shortage of affordable insulin supplies, exacerbating the global disease burden. Governments and nonprofit organizations have stepped up efforts to make life-saving insulin analogs widely available to low income group patients. However, it will take many years for universal access and coverage of diabetes treatment needs to become a reality across all nations. In the interim, the steadily augmenting diabetes patient pool will continue fueling demand for all classes of insulin, including fast acting short insulin analogs.

Market Driver - Technological advancements in insulin delivery

Technological innovation in insulin therapy has progressed at a rapid pace over the past couple of decades, led by advancement like insulin pens, insulin pumps and newly invented smart insulin delivery systems. One of the key areas of innovation is in developing more user-friendly devices that can mimic the natural insulin release patterns of pancreas more closely. Short acting insulin analogs are integral components of such advanced insulin delivery mechanisms, allowing for tighter glucose control through precise, on-demand insulin dosing.

For example, insulin pens have emerged as a preferred format for administering short acting insulin before meals. Pre-filled, disposable pens provide individually set doses of insulin in an easy-to-use format without any required mixing steps. This has boosted patient adherence and accuracy of dosing. Similarly, insulin pumps that continuously deliver short acting insulin based on changing blood glucose levels through catheters, have revolutionized flexibility and quality of life for many diabetes patients. The futuristic "artificial pancreas" system uses automated algorithms to infuse precise minute-by-minute doses of short insulin with zero user intervention, thereby achieving glucose levels in natural target range. Other smart insulin delivery innovations like dual hormone pumps, insulin patches are also highly dependent on quick acting insulin properties. Technological breakthroughs expanding access to such user-centered insulin solutions will catalyze demand upsurge for matching short acting insulin products in the coming years.

Market Challenge - High cost of insulin products

One of the major challenges faced by the short-acting insulin market is the high cost of insulin products. Insulin is a life-saving drug for millions of diabetics worldwide. However, the increased cost of insulin over the years has made it difficult for many patients to afford and properly manage their condition. The costs of insulin analogs which are preferred by many due to their faster action has risen significantly over the past decade. For example, the cost of popular insulin brand Humalog has risen by over 1,000% since it came to the market in 1996. Such steep price increases have negatively impacted insulin access and affordability. It has been reported that about one-fourth of diabetic patients ration their insulin due to the high costs, which can have severe health consequences. Additionally, the budget impact of the high drug costs on public healthcare systems and private insurance has continued to climb each year. This poses financial sustainability challenges. Addressing the rising insulin prices is urgently needed to improve patient outcomes and reduce the socioeconomic burden of diabetes.

Market Opportunity - Expansion into emerging markets

One major opportunity area for the short-acting insulin market is the expansion into emerging economies. It is estimated that over 80% of people with diabetes worldwide live in low and middle-income countries. The rising prevalence of diabetes in emerging nations like India, Brazil, China and others present a substantial patient population needing treatment. However, access to insulin in these regions has remained low due to various factors such as low healthcare infrastructure and low affordability. If insulin manufacturers can make suitable pricing and distribution strategy changes to cater to these markets, it can drive significant revenue growth. Some strategies that can be adopted are developing low-cost vial and cartridge insulin products, improving supply chain logistics to remote areas, establishing partnerships with local healthcare providers and government bodies for volume-based pricing. By tapping into the commercial potential in emerging markets, companies can boost overall sales volumes and also fulfill their role in enhancing public health.

Companies have focused on developing next-generation fast-acting insulin analogs with improved pharmacokinetic and pharmacodynamic properties. For example, in 2019, Eli Lilly launched Insulin Lispro, an ultra-rapid acting insulin analog that starts working faster than other short-acting insulins. Clinical trials showed it controls blood sugar levels more effectively post-meals. This helped Eli Lilly gain market share as Insulin Lispro set a new benchmark for fast-acting insulin therapy.

Players have formed strategic alliances with leading drug delivery device makers to launch insulin products integrated with human-centric devices. For instance, in 2021, Novo Nordisk partnered with Companion Medical to launch Fiasp Flextouch, a prefilled pen combining its fast-acting insulin Fiasp with Companion's smart insulin delivery system. This helped expand Novo Nordisk's connected care offerings, fueling a 14% sales growth in its diabetes care segment.

Companies have focused on expanding availability of their insulin brands in high growth regions. For example, in 2018 Sanofi launched its Lyxumia insulin pen in key Latin American markets like Brazil, Mexico after gaining regulatory approvals. This helped Sanofi gain 8% value share in Latin America's insulin market within a year by addressing local needs of flexibity and affordability.

Insights, By Type: In terms of type, insulin lispro sub-segment contributes the highest share of the market owing to its rapid action profile

Insulin lispro sub-segment accounts for the largest share of 40.25 in the short-acting insulin market due to its rapid action profile. Insulin lispro is the first commercially available rapid-acting insulin analogue. It was developed by substituting the amino acid proline with lysine at position B28. This single amino acid substitution results in quicker absorption and faster onset of action as compared to regular human insulin. Insulin lispro has an onset of action within 15 minutes and achieves maximum effectiveness in 30-90 minutes. Its effect lasts for 2-4 hours which makes it an ideal short-acting insulin option for patients to use before meals. The rapid action profile of Insulin Lispro more closely mimics the natural secretion of insulin by the pancreas in response to a meal. This provides better glycemic control to patients with diabetes. Moreover, Insulin Lispro is widely available as an affordable biosimilar and has gained broad acceptance among physicians as the standard of care for pre-meal insulin treatment. Its early establishment and preferential adoption by healthcare providers and insurance companies has enabled this segment to capture the largest share in the market over the years.

Insights, By Indication: Type 1 diabetes sub-segment contributes the highest share of 55.6% in the market owing to complete dependency on external insulin

The type 1 diabetes sub-segment holds the highest market share of 55.6% among indications in the short-acting insulin market. Type 1 diabetes, previously known as juvenile diabetes, is an autoimmune condition in which the body's immune system destroys the insulin-producing beta cells in the pancreas. Patients with type 1 diabetes do not produce any insulin internally and are completely dependent on lifelong external insulin administration. Short-acting insulin products are critical for Type 1 diabetes patients as they need to inject them before each meal to regulate post-prandial blood glucose levels. The nature of the condition makes insulin treatment a medical necessity for individuals with type 1 diabetes. Additionally, incidence and prevalence of type 1 diabetes is rising globally, driving increased demand for fast-acting insulin analogues among this patient segment. Early initiation and lifelong reliance on insulin therapy ensures a consistent patient base captured by this indication in the short-acting insulin market.

The short-acting insulin market is experiencing steady growth driven by the rising prevalence of diabetes, particularly in Asia-Pacific. Companies are focusing on innovations in delivery systems and biosimilar development to gain a competitive edge. The market is characterized by significant competition among major players, with a strong emphasis on research and development to introduce more effective and patient-friendly products.

The major players operating in the short-acting insulin market include Novo Nordisk, Sanofi, Eli Lilly and Company, Biocon and Adocia.

• In June 2023, Novo Nordisk launched an advanced insulin delivery device aimed at improving patient adherence.
• In April 2024, Eli Lilly and Company partnered with a digital health company to enhance diabetes management through AI-based solutions.

• By Type
  • Insulin Lispro
  • Insulin Aspart
  • Insulin Glulisine
• By Indication
  • Type 1 Diabetes
  • Type 2 Diabetes